StockNews.com Initiates Coverage on Aeterna Zentaris (NASDAQ:AEZS)

Posted by on Apr 12th, 2023

StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $28.00 price objective on shares of Aeterna Zentaris in a research note on Tuesday, March 28th.

Aeterna Zentaris Stock Performance

Shares of AEZS stock opened at $2.64 on Wednesday. The company has a 50-day simple moving average of $3.08 and a 200 day simple moving average of $3.48. The company has a market capitalization of $12.83 million, a price-to-earnings ratio of -0.57 and a beta of 1.37. Aeterna Zentaris has a 52 week low of $2.32 and a 52 week high of $9.07.

Aeterna Zentaris (NASDAQ:AEZS – Get Rating) (TSE:AEZ) last issued its earnings results on Thursday, March 23rd. The biopharmaceutical company reported ($0.84) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.93) by $0.09. The business had revenue of $2.49 million during the quarter, compared to analyst estimates of $1.06 million. Sell-side analysts forecast that Aeterna Zentaris will post -3.54 EPS for the current year.

About Aeterna Zentaris

(Get Rating)

Æterna Zentaris, Inc is a specialty biopharmaceutical company, which engages in the development and commercialization of therapeutics and diagnostic tests. Its product Macimorelin, is an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency. The company was founded on September 12, 1990 and is headquartered in Charleston, SC.

Featured Stories

Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.